Lucie Benešová

Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.

Lucie Benešová, Marek Minárik, Dana Jancarikova et al. · PubMed · 2010 · 62 citations

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer

Ondřej Fiala, Miloš Pešek, Jindřich Fínek et al. · Cancer Genetics · 2013 · 61 citations

Oncology, Cell Lung Cancer, Medicine +8

Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib

Ondřej Fiala, Miloš Pešek, Jindřich Fínek et al. · Neoplasma · 2016 · 61 citations · Full text

Serum Albumin, Pretreatment Serum Albumin, Medicine +15

Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.

Miloš Pešek, Lucie Benešová, Barbora Belšánová et al. · PubMed · 2009 · 41 citations

Insignificant Kras Mutations, Advanced Nsclc, Tyrosine-kinase Therapy +12

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.

Martin Svatoň, Ondřej Fiala, Miloš Pešek et al. · PubMed · 2016 · 39 citations